Format

Send to

Choose Destination
Clin Otolaryngol. 2017 Apr;42(2):218-224. doi: 10.1111/coa.12695. Epub 2016 Jul 24.

Quality of life in patients with allergic rhinitis: a clinical trial comparing the use of bilastine versus loratadine.

Author information

1
Postgraduate Program in Health Sciences, University of Southern Santa Catarina (UNISUL), Palhoça, Santa Catarina, Brazil.
2
University Hospital Professor Polydoro Ernani de São Thiago, Federal University of Santa Catarina (UFSC), Florianópolis, Santa Catarina, Brazil.

Abstract

OBJECTIVES:

The aim of this study was to determine whether there were differences in health-related quality of life of patients with allergic rhinitis treated with bilastine 20 mg compared to those treated with loratadine 10 mg.

DESIGN:

This was a prospective randomised double-blinded study.

SETTING:

Otolaryngology outpatient clinics in Criciúma, state of Santa Catarina, Brazil.

PARTICIPANTS:

Seventy-three patients, aged between 18 and 63 years, of whom 36 were treated with loratadine 10 mg and 37 with bilastine 20 mg with medication administered once a day for 10 days.

MAIN OUTCOME MEASURES:

The outcome was quality of life as assessed by the modified Rhinoconjunctivitis Quality of Life Questionnaire (RQLQm), which was applied at baseline and after 10 days of treatment.

RESULTS:

The use of bilastine 20 mg or loratadine 10 mg significantly reduced RQLQm scores after 10 days of treatment (P < 0.001); however, there was no statistically significant difference between the two treatment groups (P > 0.05).

CONCLUSIONS:

Health-related quality of life in patients with allergic rhinitis improved significantly after 10 days of treatment with loratadine and bilastine, and the effectiveness of both was equivalent.

PMID:
27385478
DOI:
10.1111/coa.12695
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center